President Obama Pushes BRAIN Initiative Forward
|
By LabMedica International staff writers Posted on 09 Apr 2013 |
In his State of the Union address, US President Obama outlined his strategy for creating jobs and building a growing, flourishing middle class by making an historic investment in medical research and development.
“If we want to make the best products, we also have to invest in the best ideas... Every dollar we invested to map the human genome returned USD 140 to our economy... Today, our scientists are mapping the human brain to unlock the answers to Alzheimer’s… Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race,” stated President Barack Obama, in the 2013 State of the Union address.
On April 2, 2012, at the White House, the President revealed an intrepid new research initiative designed to transform understanding of the human brain. Initiated with about USD 100 million in the President’s Fiscal Year 2014 Budget, the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative’s goal to help researchers find new ways to treat, cure, and even prevent brain disorders, such as epilepsy, Alzheimer’s disease, and traumatic brain injury.
The BRAIN Initiative is designed to hasten the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought. These technologies will create new ways to examine how the brain records, processes, uses, stores, retrieves vast quantities of information, and provide insights into the complex ties between behavior and brain function.
This initiative is one of the Administration’s “Grand Challenges” goals that require new developments in science and technology. In his address, the President called on research universities, companies, research foundations, and philanthropists to join with him in identifying and pursuing the Grand Challenges of the 21st century.
The BRAIN Initiative includes: major investments to jumpstart the effort: The US National Institutes of Health (NIH; Bethesda, MD, USA), the Defense Advanced Research Projects Agency (DARPA; Arlington, VA, USA) , and the US National Science Foundation (Arlington, VA, USA) will support approximately USD 100 million in research beginning in FY 2014. Strong academic leadership: The NIH will establish a high-level working group cochaired by Dr. Cornelia Bargmann (The Rockefeller University; New York, NY, USA) and Dr. William Newsome (Stanford University; Stanford, CA, USA) to clarify detailed scientific goals for the NIH’s investment, and to develop a multiyear scientific plan for achieving these goals, including timetables, milestones, and cost estimates.
In the 10 years alone, scientists have made a number of landmark discoveries that now create the opportunity to gain further knowledge of the brain, including the sequencing of the human genome, the increasing resolution of imaging technologies, the development of new tools for mapping neuronal connections, and the expansion of nanoscience. These innovations have offered a chance for unprecedented collaboration and discovery across scientific fields. For instance, by combining sophisticated genetic and optical technologies, scientists can now use pulses of light to determine how specific cell activities in the brain affect behavior. Moreover, through the integration of neuroscience and physics, researchers can now use high-resolution imaging technologies to observe how the brain is structurally and functionally connected in living humans.
Whereas these technologic contributions have substantially added to expanding knowledge of the brain, significant breakthroughs in how physicians treat neurologic and psychiatric disease will require a new generation of applications to enable researchers to map signals from brain cells in much greater numbers and at even faster speeds. This cannot presently be accomplished, but great potential for developing such technologies lies at the crossroads of imaging, nanoscience, engineering, informatics, and other rapidly budding fields of science and engineering.
Related Links:
US National Institutes of Health
US Defense Advanced Research Projects Agency
US National Science Foundation
“If we want to make the best products, we also have to invest in the best ideas... Every dollar we invested to map the human genome returned USD 140 to our economy... Today, our scientists are mapping the human brain to unlock the answers to Alzheimer’s… Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race,” stated President Barack Obama, in the 2013 State of the Union address.
On April 2, 2012, at the White House, the President revealed an intrepid new research initiative designed to transform understanding of the human brain. Initiated with about USD 100 million in the President’s Fiscal Year 2014 Budget, the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative’s goal to help researchers find new ways to treat, cure, and even prevent brain disorders, such as epilepsy, Alzheimer’s disease, and traumatic brain injury.
The BRAIN Initiative is designed to hasten the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought. These technologies will create new ways to examine how the brain records, processes, uses, stores, retrieves vast quantities of information, and provide insights into the complex ties between behavior and brain function.
This initiative is one of the Administration’s “Grand Challenges” goals that require new developments in science and technology. In his address, the President called on research universities, companies, research foundations, and philanthropists to join with him in identifying and pursuing the Grand Challenges of the 21st century.
The BRAIN Initiative includes: major investments to jumpstart the effort: The US National Institutes of Health (NIH; Bethesda, MD, USA), the Defense Advanced Research Projects Agency (DARPA; Arlington, VA, USA) , and the US National Science Foundation (Arlington, VA, USA) will support approximately USD 100 million in research beginning in FY 2014. Strong academic leadership: The NIH will establish a high-level working group cochaired by Dr. Cornelia Bargmann (The Rockefeller University; New York, NY, USA) and Dr. William Newsome (Stanford University; Stanford, CA, USA) to clarify detailed scientific goals for the NIH’s investment, and to develop a multiyear scientific plan for achieving these goals, including timetables, milestones, and cost estimates.
In the 10 years alone, scientists have made a number of landmark discoveries that now create the opportunity to gain further knowledge of the brain, including the sequencing of the human genome, the increasing resolution of imaging technologies, the development of new tools for mapping neuronal connections, and the expansion of nanoscience. These innovations have offered a chance for unprecedented collaboration and discovery across scientific fields. For instance, by combining sophisticated genetic and optical technologies, scientists can now use pulses of light to determine how specific cell activities in the brain affect behavior. Moreover, through the integration of neuroscience and physics, researchers can now use high-resolution imaging technologies to observe how the brain is structurally and functionally connected in living humans.
Whereas these technologic contributions have substantially added to expanding knowledge of the brain, significant breakthroughs in how physicians treat neurologic and psychiatric disease will require a new generation of applications to enable researchers to map signals from brain cells in much greater numbers and at even faster speeds. This cannot presently be accomplished, but great potential for developing such technologies lies at the crossroads of imaging, nanoscience, engineering, informatics, and other rapidly budding fields of science and engineering.
Related Links:
US National Institutes of Health
US Defense Advanced Research Projects Agency
US National Science Foundation
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
Primary central nervous system lymphoma (PCNSL) is typically diagnosed through surgical biopsy, which remains the gold standard but carries substantial risk. Operability depends heavily on tumor location,... Read more
New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, marked by poor survival rates and limited treatment options, especially in patients who do not respond to standard therapies.... Read moreHematology
view channel
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channelAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read morePathology
view channel
AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
Accurately identifying genetic mutations is central to cancer diagnostics and genomic research, but current methods struggle with complex sequencing data and limited clinical samples. Tumor analysis often... Read more
Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
Transthyretin amyloidosis (ATTR) is a rare, progressive, and highly aggressive disease caused by the misfolding of a specific protein that accumulates as toxic amyloid filaments in multiple organs.... Read moreTechnology
view channelAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







